We are live on ! Find out more
BCAX

Bicara Therapeutics
BCAX

69 hedge funds and large institutions have $928M invested in Bicara Therapeutics in 2024 Q3 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

66.96% more ownership

Funds ownership: 0% → 66.96% (+67%)

Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
0.99%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$177M
2
TGA
TPG GP A
Texas
+$76.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$58M
4
OFM
Omega Fund Management
Massachusetts
+$56.2M
5
DM
Deerfield Management
New York
+$45.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
26
OrbiMed
New York
$6.93M +$6.93M +271,910 New
Citadel Advisors
27
Citadel Advisors
Florida
$5.96M +$5.97M +234,122 New
ITP
28
Iron Triangle Partners
Connecticut
$5.09M +$5.1M +200,000 New
Ameriprise
29
Ameriprise
Minnesota
$5.09M +$5.1M +200,000 New
BC
30
Boxer Capital
California
$3.44M +$3.44M +135,000 New
NIP
31
Nicholas Investment Partners
California
$2.99M +$3M +117,523 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$2.61M +$2.61M +102,420 New
Goldman Sachs
33
Goldman Sachs
New York
$2.6M +$2.6M +101,895 New
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$1.85M +$1.86M +72,807 New
Norges Bank
35
Norges Bank
Norway
$1.78M +$1.79M +70,000 New
Vanguard Group
36
Vanguard Group
Pennsylvania
$1.78M +$1.79M +70,000 New
PD
37
Point72 (DIFC)
United Arab Emirates
$1.42M +$1.42M +55,757 New
MS
38
Maven Securities
Jersey
$1.27M +$1.28M +50,000 New
Geode Capital Management
39
Geode Capital Management
Massachusetts
$1.24M +$1.24M +48,639 New
Squarepoint
40
Squarepoint
New York
$1.14M +$1.14M +44,774 New
ACM
41
ADAR1 Capital Management
Texas
$1.03M +$1.03M +40,440 New
SB
42
Samsara BioCapital
California
$891K +$893K +35,000 New
Walleye Capital
43
Walleye Capital
New York
$809K +$810K +31,780 New
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$582K +$583K +22,859 New
SFM
45
Soros Fund Management
New York
$509K +$510K +20,000 New
PAS
46
Point72 Asia (Singapore)
Singapore
$462K +$462K +18,125 New
SRL
47
Scientech Research LLC
New Jersey
$458K +$458K +17,973 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$439K +$439K +17,227 New
LCM
49
Legato Capital Management
California
$361K +$362K +14,179 New
TRSOTSOK
50
Teachers Retirement System of the State of Kentucky
Kentucky
$358K +$358K +14,039 New
1
2
3

BCAX Hedge Fund Activity: Q3 2024 in Review

69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q3 2024, worth a combined $928M.

Buyers outnumbered sellers: 69 funds opened new BCAX positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $177M.

  • 69 institutional investors held Bicara Therapeutics (BCAX) as of Q3 2024, up from 0 in Q2 2024.
  • Funds reported $928M of Bicara Therapeutics stock for Q3 2024.
  • 69 funds opened new Bicara Therapeutics positions in Q3 2024 and 0 closed out, a net change of +69 holders.
  • The largest Bicara Therapeutics buyer in Q3 2024 was RA Capital Management, an estimated $177M added.

Based on aggregated 13F filings for Q3 2024.